Creabilis begins state of matter IIb trial of TrkA Kinase Inhibitor CT327 in psoriasis pharmabiz.com Creabilis SA, a European biotechnology establishment specialising in the development of treatments for dermatology, inflammation and pain, has initiated the phase IIb global clinical trial of its lead product CT327 in patients with disease of the skin vulgaris. and more » Link To Article
No comments:
Post a Comment